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Abstract 
Objective: Variation in the use of tests and treatments has been demonstrated to be 
substantial between providers and geographic regions. This study assessed variation between 
outpatient providers in overriding electronic prescribing warnings. 
Methods: Responses to warnings were prospectively logged. Random effects models were used 
to calculate provider-to-provider variation in the rates for the decisions to override warnings in 
six different clinical domains – medication allergies, drug-drug interactions, duplicate drugs, 
renal recommendations, age-based recommendations, and formulary substitutions. 
Results: A total of 157,482 responses were logged. Differences between 1,717 providers 
accounted for 11% of the overall variability in override rates, so that while the average override 
rate was 45.2%, individual provider rates had a wide range with a 95% confidence interval (CI) 
of [13.7%, 76.7%]. The highest variations between providers were observed in the categories 
age-based (25.4% of total variability; average override rate 70.2%; 95% CI [29.1%, 100%]) and 
renal recommendations (24.2%; average 70.0%; 95% CI [29.5%, 100%]), and provider responses 
within these two categories were most often clinically inappropriate according to prior work. 
Among providers who received at least 10 age-based recommendations, 64 (27%) overrode 
≥90% of the warnings and 13 (5%) overrode all of them. Of those who received at least 10 renal 
recommendations, 36 (39%) overrode ≥90% of the alerts and 9 (10%) all of them. 
  
Conclusions: The decision to override prescribing warnings shows variation between providers, 
and the magnitude of variation differs among the clinical domains of the warnings; more 
variation was observed in areas with more inappropriate overrides.  
  
Background 
Variation in health care across regions and providers has been studied for several decades.1 
Wennberg summarized the main findings in his seminal article of 1973,2 stating that (i) they 
found extensive variation in health care delivery, (ii) patients underwent disproportionally more 
surgical procedures in areas with more surgeons as well as more diagnostic tests in areas with 
more internists, and (iii) health care costs did not correlate with age-adjusted mortality.3 
The variation in the incidence of surgical procedures is well-known,4 especially for some 
discretionary procedures such as hysterectomies5,6 and tonsillectomies.7 A recent study 
presented variations in diagnostic management depending on the intensity of practice between 
areas.8 Further, it has been demonstrated that patients who live in regions with hospitals of 
higher bed capacity have a substantially higher chance of being hospitalized – unrelated to the 
disease burden and without benefit for these patients.9 In another study, the adherence of 
heart failure patients to their home medication varied by geographic region.10 
Although there are published data on variations in prescribing behavior,11,12 little is known 
about variations in provider responses to electronic prescribing warnings generated by clinical 
decision support (CDS) systems.13 A recent analysis in our institution showed that electronic 
warnings were overridden in up to 85% of cases, and chart reviews revealed that the 
appropriateness of overriding alerts varied dramatically by category of alert type, ranging from 
12% to 92% depending on the clinical domain.14 However, variations between the providers in 
terms of how much they differ in their decisions about whether to follow or override electronic 
prescribing recommendations has not been analyzed. Because of the wide adoption of 
electronic health records, such data are now widely available, and they may have a number of 
  
implications on safety improvement and assessment of provider behavior. In addition, 
overriding important safety warnings may represent unsafe practice; when drivers repeatedly 
violate rules such as those about stopping for stop signs and red lights, they expose others to 
greater risk. We undertook this study to examine the degree of variation between providers 
about the decision to override six types of electronic prescribing warnings, and also considered 
the likelihood that these warnings were appropriate.  
  
Methods 
Design, Site and Period of the Study 
The study was a retrospective, observational cohort study. All types of outpatient prescribing 
providers were included as participants in the cohort, i.e. physicians, nurse practitioners and 
physician assistants. Data were collected from the outpatient clinics and ambulatory practices 
associated with the Massachusetts General Hospital and the Brigham and Women’s Hospital, 
two large tertiary care teaching hospitals; most of these practices were located in the 
community. Overrides of electronic warnings were prospectively logged between 1/1/2009 and 
12/31/2011. The institutional ethics committee approved the study and patient consent was 
waived. 
Electronic Notifications 
The computerized physician order entry (CPOE) system in combination with CDS analyzed in 
this study was the “Longitudinal Medical Record” (LMR), an internally developed electronic 
medical record system used by physicians and other clinical staff in the outpatient setting for 
documentation of medical care. The displayed electronic recommendations for medication 
allergies, drug-drug interactions (DDIs) and duplicate drugs were initially derived from First 
DataBank (First Databank, Inc., South San Francisco, CA), and tailored and updated by both 
review of the literature, and then based on how providers respond to the alerts, with on-going 
review by an expert committee. Renal15 and age-based16 recommendations and formulary 
substitutions alerts were internally developed for the inpatient setting, and were later adapted 
for outpatients; they have also been modified serially based on user responses. Further details 
  
on LMR and implemented CDS notifications are provided elsewhere.14 Drug safety warnings of 
six clinical domains displayed to the providers were evaluated: (i) medication allergies, (ii)  DDIs, 
(iii) duplicate drugs, (iv) renal recommendations, (v) age-based recommendations, and 
(vi) formulary substitutions. Of note, in each category, various prescribing problems due to 
various drugs led to electronic warnings. The overall number of alerts was the sum of the 
numbers derived from the six categories.  
Statistical analysis 
The primary goal was to quantify the variation between the providers in terms of their 
binary decisions to accept or override electronic prescribing recommendations. This variation 
was calculated for each clinical domain and for the aggregated total as well. Further analyses 
included the variations within providers and the override rates. 
Histograms were plotted to illustrate the distribution of the crude override rates, which 
were defined for each provider as the number of overridden warnings divided by the total 
number of received warnings. However, only providers receiving at least ten warnings were 
considered in these analyses in order to avoid distortions resulting from providers with low 
alert counts, thus often leading to override rates of 0% or 100%. Similarly, providers were 
considered in the calculations of the crude override rate for each analyzed clinical domain if 
they responded to at least ten alerts according to the respective domain. Therefore, the 
number of excluded providers varied among the analyzed alert domains. 
Random effects models (two-level hierarchical linear models) were used to calculate the 
variation between and within the providers for the binary decision to override a warning. 
Providers were eligible for inclusion if they responded to at least one alert according to the 
  
analyzed clinical domain, or one alert independent of the clinical domain in the overall analysis. 
Unlike usual regression models, the random effects model includes a term for each provider on 
the right-hand side of the regression equation which represents each provider’s own unique 
override rate.  These terms are random variables whose distribution is estimated from the 
observed data; the distribution provides a 95% confidence interval for the provider override 
rates. The random effects model produces “shrinkage” estimate of the override rates which 
remain stable even if a provider has few warnings.  Therefore, we were able to produce 95% 
confidence intervals that captured the true override rates of all providers, at both low and high 
volumes. 
Calculations were performed using the software R, version 3.0.2 (R Foundation for Statistical 
Computing, Vienna, Austria). 
  
  
Results 
A total of 1,717 providers received at least one prescription warning in one or more of the 
six analyzed clinical domains. Among the 1,099 providers who received at least ten alerts, the 
crude override rate was 53% (82,100/155,413). Nevertheless, most of these providers (662; 
60%) overrode less than 50% of the warnings (Figure 1). Only 462 providers (27%) received one 
or more alerts within each of the six domains. 
The distribution of the providers’ crude override rates in the clinical domains of the age-
based and renal recommendations were skewed to the left (Figure 2). Among providers who 
received at least ten age-based recommendations, 64 (27%) overrode ≥90% of the warnings 
and 13 (5%) overrode all of them. Of those who received at least ten renal recommendations, 
36 (39%) overrode ≥90% of the alerts and 9 (10%) all of them. Notably, four (22%) of the 
mentioned 22 providers overrode all received warnings in both clinical domains (Figure 3). 
Using the random effects model, we were able to include both high and low volume 
providers and we found that between-provider differences accounted for 11% of the variability 
in decisions to override prescribing alerts (Table 1), i.e. 89% of the variation occurred within a 
provider. The average override rate measured in the aggregated total of the alerts was 45%. 
  
 
Table 1. Variation between and within providers as well as the true average override rate. 
 
Number of 
displayed alerts 
Number of 
providers 
receiving at 
least one alert 
Variation 
between 
providers 
Variation within 
providers 
Percentage of 
variation 
between 
providers 
Percentage of 
variation within 
providers 
True override 
rate 
95% confidence 
interval of the 
true  override 
rate 
Total of warnings 
157,482 1,717 0.02583 0.21002 11.0% 89.0% 45.2% [13.7%, 76.7%] 
Warnings against 
patient allergies 
26,408 1,160 0.0311 0.1461 17.6% 82.4% 68.6% [34.0%, 100%] 
Warnings against 
drug-drug interactions 
24,849 1,177 0.03338 0.20258 14.1% 85.9% 55.4% [19.6%, 91.2%] 
Warnings against 
duplicate drugs 
75,889 1,606 0.02683 0.17498 13.3% 86.7% 29.2% [0%, 61.3%] 
Formulary 
substitution 
recommendations 
15,945 1,067 0.02042 0.11245 15.4% 84.6% 79.5% [51.5%, 100%] 
Age-based 
recommendations 
10,501 827 0.04402 0.12938 25.4% 74.6% 70.2% [29.1%, 100%] 
Renal 
recommendations 
3,890 584 0.04279 0.1337 24.2% 75.8% 70.0% [29.5%, 100%] 
 
  
Among the six clinical domains, the highest magnitudes of between-provider variability were 
25% (75% variation within) and 24% (76% variation within) in the categories “age-based 
recommendations” and “renal recommendations”, respectively. These were also the domains 
in which provider responses were often clinically inappropriate according to prior work.14 The 
percentages of variation between providers in the remaining four clinical domains ranged from 
13% (duplicates) to 18% (allergies), in addition, the lowest average override rate was measured 
within the domain of the warnings against duplicate drugs (29%). The highest average override 
rate was measured for formulary substitution recommendations (79%). 
In particular, the age-based and renal recommendations had the highest magnitudes of 
variation between providers; however, the numbers of displayed alerts in these categories 
accounted for the two smallest proportions among the clinical domains. This was true 
independent of the number of received alerts per provider: If a provider received on average 
1.9 alerts (mean number of the lowest quartile) then renal recommendations represented the 
smallest proportion (1.1%) followed by age-based recommendations (4.1%), formulary 
substitution recommendations (8.2%), warnings against drug-drug interactions (12.9%), 
warnings against patient allergies (12.9%), and warnings against duplicate drugs (60.8%). If a 
provider received 307.9 alerts (mean number of the highest quartile) then the proportions were 
2.6%, 7.2%, 10.2%, 16.2%, 17.7%, and 46.1%, respectively. 
  
  
Discussion 
We found that decisions to override electronic prescribing warnings showed variation 
between providers, and the magnitudes of variation differed among the clinical domains of the 
warnings. Regarding the overall analysis, the provider responses varied moderately with a 
percentage of variation of 11%. However, the percentage of variation in responses to electronic 
recommendations for age-based and renal prescribing was 25% and 24%, respectively, and thus 
substantially higher than the variation in responses to warnings of the other domains, ranging 
from 13% to 18%. This is important because in prior work we had found that overridden age-
based and renal recommendations are likely to be inappropriate.14 The high proportion of 
variation measured within providers may be explained in part by changes in providers’ behavior 
around whether or not they are familiar with a particular patient, for instance a provider would 
(and should) override allergy warnings to a medication they know the patient is already 
tolerating.11 However, a few providers overrode all or nearly all the warnings they saw, even in 
important categories, and this is almost certainly unsafe. 
Researchers have observed medical practice variation for many conditions and procedures.17 
Nevertheless, relatively little is known about variation in the providers’ responses to electronic 
prescribing recommendations.13 Articles have been published on variation in ordering behavior, 
integrating costs as a proxy.11,12 For example, Schroeder et al. found a 4.4-fold variation in drug 
use between 33 internists, and also that lab costs (17-fold variation) were significantly 
correlated with the drug costs per provider.11 Zhang et al. observed only a 1.6-fold variation in 
the drug costs among Medicare beneficiaries between geographic regions; however, the use of 
  
high-risk medication varied 3.9-fold, and the awareness of drug-disease interactions varied 4.1, 
8.6, and 7.8-fold for dementia, hip or pelvic fracture, and chronic renal failure, respectively.12 
We used random effects models to characterize the mean variations between health care 
providers in their decisions to override or follow electronic recommendations for six clinical 
domains as well as for the aggregated total of these alerts. A recent study calculated the 
median absolute deviation (MAD) for a number of defined management decisions to describe 
the variation between 18 cancer centers.18 The authors based their choice of the MAD on the 
robustness to outliers. However, outliers were not a specific concern in the present study, 
because the variation was calculated between a total of 1,717 providers considering 157,482 
warning responses. 
High variation – especially if in an area in which there is also considerable inappropriateness 
– can indicate potential to improve care. One research group implemented interventions into 
their CPOE system to reduce unnecessary lab tests, and notably, measured a significant 
reduction of variation in ordering bundle tests and in ordering electrocardiograms.19 After the 
dissemination of data on geographic variation of tonsillectomy rates among 13 areas in 
Vermont, another group found a 46% reduction of the overall tonsillectomy rates.7 
In this study, the variations between providers for accepting or overriding age-based and 
renal recommendations were much higher than for other categories of warnings, i.e. different 
providers varied more in how they responded to these categories, whereas override rates in 
the other four alert categories were more similar from one provider to another. This was the 
case even though we had also previously found substantial clinical benefits from introduction of 
age-based and renal recommendations.15,16 However, in these initial studies, we did not follow 
  
up on the overrides. Since high proportions of inappropriate overrides had been observed 
among age-based recommendations and renal recommendations,14 targeted feedback to select 
providers might increase adherence to guidelines and improve quality of care.20 These data 
could also be used in credentialing, as they are likely to be much more objective and clinically 
meaningful, than for example the clinical assessment of a peer, which is what is mainly used 
today. However, anything being used for credentialing should be validated carefully before it is 
used. Data like this represent one more stream of the “big data” that will be available from 
electronic records in the future.21 While much of the focus on big data has been on patient 
data, multiple streams of data will also be available about providers. 
On the one hand, many warnings about issues such as drug-drug interactions may be 
unnecessary and can contribute to alert fatigue. On the other hand, some drug-drug 
interactions clearly cause substantial harm — for example, Juurlink et al. have shown at the 
population level that when some medications are started together the readmission goes up 
substantially.22 Along with reducing the burden of clinically insignificant alerts, patient-specific 
services have been shown to achieve high acceptance rates among clinicians.23–25 However, a 
study by Nanji et al. also underscored that not all warnings should be accepted, for example, 
more than three quarters of the patient allergy warnings had been overridden, but 92% of 
these overrides were appropriate.14 One implication is that it would be much better to use 
domains with high rates of inappropriately overridden warnings as a main target for 
interventions or credentialing. In this context, when assessing the appropriateness of overrides 
of prescribing warnings, it is critical to consider various reasons for overriding, since for 
example the benefit from pain medication might exceed the risk for an adverse drug event. 
  
However, not only patient-specific risks can influence the appropriateness of overrides, but also 
CPOE and alert-related factors such as the human factors characteristics of how the alerts are 
displayed need to be considered, 26 which depend on the system that has been implemented. 
Finally, a recent study investigated the influence of provider characteristics on responses to 
electronic prescribing warnings.27 
Some limitations need to be taken into account in interpreting this study. We did not assess 
how often overrides of prescribing warnings actually resulted in adverse drug events, which 
was beyond the scope of the present investigation. Further, the CPOE system was developed in-
house and displayed CDS alerts that have been tailored and updated by expert groups over 
time. However, some alert categories were derived from a proprietary database widely used in 
the U.S., with the main modification being that we turned off many unnecessary alerts. Most 
systems currently being deployed in the U.S. are using commercial EHRs installed recently, and 
thus the results with these may differ. 
We conclude that the largest part of variation was found within the individual provider, 
however, variation between the providers was substantial in responses to alerts for clinical 
domains around which a high proportion of overrides was inappropriate. It may be possible to 
use override rates to target these providers in order to improve the safety of care — as 
interventions may be warranted for drivers with defined patterns of risky behavior — and they 
could also be used for purposes such as credentialing. Override data should now be routinely 
available. Organizations should track their override rates overall and also analyze overrides by 
provider and alert type. For types of alerts that are frequently overridden appropriately, 
however, intervening at the individual level could be counter-productive.  
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Figures Legends 
Figure 1. Histogram showing the distribution of the providers’ crude override rates of the 
aggregated total of responses across all alert categories. Only providers who received at least 
10 alerts were included (1099 providers). 
 
 
  
  
Figure 2. Distributions of the providers’ crude override rates per alert category. Only providers 
who received at least 10 alerts in the respective category were included (number of providers 
shown in brackets). 
 
  
 
Figure 3. Two-dimensional plots of the crude override rates of the two clinical domains with the 
highest variation and also low appropriateness.14 One dot represents one provider. Left: Only 
providers who received at least 10 alerts in each of the two clinical domains were included. 
Right: For comparison, all providers who received at least one alert in each of the two clinical 
domains were considered (number of providers shown in brackets). 
 
 
 
